Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Background and Aim It has been reported about poor prognosis in patients with advanced hepatocellular carcinoma (HCC) refractory to hepatic arterial infusion chemotherapy (HAIC). We assessed the ...

Hepatocellular ... of primary liver cancer, is the fastest rising cause of cancer-related deaths in the United States. Texas has the highest incidence rates of HCC in the nation. To address this ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC). These data are being presented at the 2025 ASCO Gastrointestinal Cancers Symposium ...

Between June 2000 and December 2011, 295 patients with unresectable HCC were treated with HAIC at our hospital. HAIC was selected as the therapeutic option for patients with advanced HCC with PVTT ...